Global Reproductive Leader As part of the Vitrolife Group, Igenomix sits within a world-leading reproductive health ecosystem with a global footprint and a strong IVF focus. This positions us well for cross-sell opportunities combining genetic testing services with medical devices across many markets and distribution channels, framed by a sustainability-driven, quality-first mandate.

Integrated Solutions Opportunity to bundle Igenomix genetic testing services with Vitrolife medical devices and end-to-end workflow solutions to offer clinics a comprehensive reproductive-health platform. Leverage existing products like Embrace and non-invasive tests to streamline clinic operations and improve treatment outcomes.

Strategic Partnerships Current collaborations such as the Ferring partnership in infertility and pregnancy-related conditions create avenues for co-developed diagnostics and therapeutics and joint go-to-market strategies. Utilize pharma and research channels to broaden clinic reach and accelerate adoption of genetic testing.

Non-Invasive Growth Historical advancement in non-invasive endometrial receptivity testing demonstrates demand for patient-friendly diagnostics. Position Igenomix as a leader in non-invasive testing within IVF workflows and cross-sell with genetic testing to boost diagnostic adoption and treatment planning.

Sustainable Quality Vitrolife’s emphasis on sustainability, science-based research, and consistent quality control provides a differentiator for clinics seeking reliable, long-term partnerships. Frame offerings around quality assurance, regulatory compliance, and sustainable supply chains to support clinic trust and retention.